The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Highlights from the IASLC 2022 World Conference on Lung Cancer congress
Julia Rotow, MD, Dana-Farber Cancer Institute, Boston, MA, shares her highlights from the IASLC 2022 World Conference on Lung Cancer congress, including data presented on KRASG12C combinations such as a low-dose KRAS inhibitor with pembrolizumab which demonstrated responses in patients who had progressed on checkpoint inhibitors. Additionally, data on hepatotoxicity of KRAS inhibition when combined with checkpoint inhibitors, either when given concurrently or following treatment with checkpoint inhibitors is discussed. Dr Rotow also mentions the novel bispecific antibody (BiTE), tarlatamab, which is under investigation in small cell lung cancer (SCLC) and currently demonstrating encouraging results. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
